AVBP Earnings
ArriVent BioPharma, Inc.
1W: -18.3%
1M: -47.4%
3M: -48.7%
YTD: -26.0%
1Y: -17.2%
$15.40
+0.04 (+0.26%)
Weekly Expected Move ±26.1%
$10
$16
$21
$26
$32
Credit Risk of going bust: lower than 76% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), ArriVent BioPharma, Inc. would be worth roughly what it owes.
Total debt $351K against a stock market value of $759.3M.
Distance to default 8.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $176K (short-term plus half of long-term), stock volatility 91.5%; Altman Z'' 13.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), ArriVent BioPharma, Inc. would be worth roughly what it owes.
Total debt $351K against a stock market value of $759.3M.
Distance to default 8.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $176K (short-term plus half of long-term), stock volatility 91.5%; Altman Z'' 13.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Last Earnings
2026-08-12
EPS
$-1.05
▼ Miss -6.4%
Revenue
—
Next Earnings
2026-11-16
EPS Estimate
$-1.09
Range: $-1.15 - $-1.04
Revenue Estimate
$6M
6 analysts
Estimate vs Actual
Earnings Surprise History
5/16
EPS Beats
0/16
Revenue Beats
31%
EPS Beat Rate
0%
Rev Beat Rate
Wall Street Forward Estimates
Quarterly
Annual
Estimate Revisions
Recent Revisions
| Date | Period | Fiscal Date | EPS Old | EPS New | Change | Rev Old | Rev New |
|---|---|---|---|---|---|---|---|
| 2026-10-22 | annual | 2027-12-31 | $-3.86 | $-3.74 | ▲ 0.12 | $6,740,455 | $6,740,455 |
| 2026-10-22 | quarter | 2026-12-30 | $-1.10 | $-1.09 | ▲ 0.01 | $6,050,000 | $6,050,000 |
| 2026-10-22 | annual | 2030-12-31 | $0.46 | $-0.15 | ▼ 0.61 | $296,250,833 | $243,061,167 |
| 2026-10-22 | annual | 2029-12-31 | $-1.44 | $-1.74 | ▼ 0.30 | $155,955,333 | $123,257,333 |
| 2026-10-22 | annual | 2028-12-31 | $-2.82 | $-2.80 | ▲ 0.02 | $53,818,490 | $37,922,740 |
| 2026-10-22 | quarter | 2026-09-30 | $-1.06 | $-1.05 | ▲ 0.01 | $800,000 | $800,000 |
| 2026-10-22 | annual | 2026-12-31 | $-4.24 | $-4.23 | ▲ 0.01 | $125,000 | $125,000 |
| 2026-10-19 | annual | 2029-12-31 | $-1.32 | $-1.44 | ▼ 0.12 | $158,255,333 | $155,955,333 |
| 2026-10-19 | annual | 2028-12-31 | $-2.73 | $-2.82 | ▼ 0.09 | $54,393,490 | $53,818,490 |
| 2026-10-19 | annual | 2030-12-31 | $0.83 | $0.46 | ▼ 0.37 | $301,567,500 | $296,250,833 |
| 2026-10-19 | annual | 2027-12-31 | $-3.89 | $-3.86 | ▲ 0.03 | $7,314,500 | $6,740,455 |
| 2026-10-19 | quarter | 2026-12-30 | $-1.09 | $-1.10 | ▼ 0.01 | $6,050,000 | $6,050,000 |
| 2026-10-19 | quarter | 2026-09-30 | $-1.07 | $-1.06 | ▲ 0.01 | $800,000 | $800,000 |
| 2026-10-19 | annual | 2026-12-31 | $-4.23 | $-4.24 | ▼ 0.01 | $125,000 | $125,000 |
| 2026-10-09 | annual | 2027-12-31 | $-3.93 | $-3.89 | ▲ 0.04 | $9,576,000 | $7,314,500 |
Earnings Call Transcripts
No transcripts available.